Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) – Analysts at HC Wainwright boosted their Q1 2023 earnings per share (EPS) estimates for shares of Entera Bio in a research report issued on Tuesday, April 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.14). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Entera Bio's current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Entera Bio's Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.19) EPS, Q4 2023 earnings at ($0.21) EPS and FY2023 earnings at ($0.66) EPS.

Entera Bio Stock Down 6.4 %

Shares of ENTX stock opened at $0.86 on Thursday. The stock has a market cap of $24.80 million, a PE ratio of -1.91 and a beta of 1.83. The business has a 50-day simple moving average of $1.01 and a 200-day simple moving average of $0.88. Entera Bio has a 52-week low of $0.47 and a 52-week high of $3.00.

Hedge Funds Weigh In On Entera Bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in Entera Bio by 555.4% in the 4th quarter. Renaissance Technologies LLC now owns 139,600 shares of the company's stock worth $102,000 after purchasing an additional 118,300 shares during the period. Millennium Management LLC raised its holdings in Entera Bio by 358.5% in the 4th quarter. Millennium Management LLC now owns 46,000 shares of the company's stock worth $34,000 after purchasing an additional 35,968 shares during the period. Finally, PNC Financial Services Group Inc. acquired a new position in Entera Bio in the 1st quarter worth about $29,000. Institutional investors and hedge funds own 20.12% of the company's stock.

Insider Activity

In related news, CEO Miranda Jayne Toledano acquired 30,000 shares of the firm's stock in a transaction dated Tuesday, April 4th. The stock was acquired at an average price of $1.01 per share, with a total value of $30,300.00. Following the acquisition, the chief executive officer now directly owns 86,800 shares in the company, valued at approximately $87,668. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 5.15% of the company's stock.

Entera Bio Company Profile

(Get Rating)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Featured Stories

• Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
• Hypercharge Networks: Up Triple Digits, But What's The Big Deal?
• 3 Reasons Why Apple's 30% Rally Has Legs
• 3 Reasons to Pick First Citizens Instead of First Republic Bank
• 3 April Earnings Plays for Bullish Swing Traders
• Is Constellation Brands Star About To Rise?

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.